Brief: Tenaya Therapeutics Receives FDA Fast Track Designation For TN-201
02/05/2023 13:17
May 2 (Reuters) - Tenaya Therapeutics Inc TNYA.O :
* TENAYA THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION
FOR
TN-201
* TENAYA THERAPEUTICS INC - DOSING IN PHASE 1 CLINICAL TRIAL
EXPECTED TO COMMENCE IN Q3 2023
Source text for Eikon: ID:nGNXbKlTfW
Further company coverage: TNYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027